CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic growth hormone-releasing hormone (GHRH) analog widely studied for its ability to support sustained endogenous growth hormone release and endocrine function. The incorporation of the Drug Affinity Complex (DAC) significantly extends the peptide’s half-life, allowing for prolonged biological activity and making it an important research compound for investigating long-term growth hormone physiology and metabolic regulation.
Researchers investigate CJC-1295 with DAC for its potential role in stimulating the pituitary gland to promote the body’s natural pulsatile release of growth hormone. It is commonly studied for its influence on protein synthesis, lean muscle development, tissue regeneration, cellular repair, body composition, and metabolic efficiency. Its prolonged duration of action also makes it valuable for examining sustained growth hormone signaling and its effects on muscle physiology, recovery, and healthy aging.
In addition, CJC-1295 with DAC has become a significant focus of research involving exercise physiology, regenerative medicine, endocrinology, and longevity science. By providing extended stimulation of endogenous growth hormone pathways, it offers researchers valuable insight into the mechanisms governing anabolic signaling, tissue remodeling, fat metabolism, and long-term endocrine regulation.
Reviews
There are no reviews yet.